Sionna Therapeutics Earnings Call Transcripts
Fiscal Year 2026
-
The company is advancing two NBD1 stabilizers for cystic fibrosis, targeting significant unmet need with both add-on and dual combination strategies. Key clinical data from ongoing studies are expected by mid-2026, supported by strong financial resources and a validated predictive assay.
-
The discussion highlighted the strategy to address unmet needs in CF by developing NBD1 stabilizers, with a focus on dual combinations aiming for clinically meaningful improvements in CFTR function. The phase II study is designed for robust mechanistic proof, and future plans include dose-ranging and co-formulation.
-
The summit highlighted a novel approach to CF treatment using NBD1 stabilizers, with key phase 2a and dual combination studies targeting mid-2026 data. The company aims to address unmet needs in a growing $12–17 billion market, supported by strong financials.
-
Focused on NBD1 stabilization, the company is advancing two lead programs targeting the F508del mutation in CF, with pivotal data expected mid-2026. Both add-on and dual combination strategies aim to surpass current standards, addressing a $12B+ market and significant unmet need.
Fiscal Year 2025
-
A differentiated approach to cystic fibrosis targets the NBD1 domain with two main clinical strategies, aiming for superior efficacy and broad patient impact. Strong financials support development through 2028, with pivotal data expected in mid-2026 and a focus on maximizing patient access and commercial opportunity.
-
Significant clinical progress was made with NBD1 stabilizers, including phase I completions and the launch of key phase II and combination studies. The team aims to address unmet needs in CF by improving CFTR function and is confident in their assay's predictive power, with pivotal data expected in mid-2026.
-
The team is advancing two NBD1 stabilizers for cystic fibrosis, aiming to improve CFTR function beyond current standards. Key phase IIa and dual combination studies are underway, with data expected mid-2026 and a strong cash position supporting development.
-
The company is advancing NBD1-targeted therapies for CF, with two clinical studies (add-on and dual combo) expected to read out in mid-2026. Both programs leverage validated assays and strong financials, aiming to surpass current standards in CFTR function restoration.
-
Significant progress was highlighted in advancing two NBD1 stabilizers for cystic fibrosis, with both compounds exceeding early clinical targets and two phase 2a trials expected to report data by mid-2026. The company is well-funded, targeting a large, growing market, and aims to deliver best-in-class therapies that address major unmet needs.
-
Two NBD1 stabilizers exceeded Phase 1 targets and are advancing as an add-on and in dual combinations, with key readouts expected mid-2026. The approach targets significant unmet need in cystic fibrosis, aiming for clinical superiority over current standard of care.
-
The company is advancing two NBD1 stabilizers for cystic fibrosis, with SION-719 moving to phase II-A as an add-on to standard care and SION-451 prioritized for dual combination studies. Both trials start in H2 2024, with data expected mid-2026, supported by a strong financial position.
-
Phase I data for SION-719 and SION-451 in healthy volunteers showed both exceeded PK targets and had favorable safety, supporting advancement into phase II-A and dual combination trials for CF. SION-719 will be tested as an add-on to Trikafta, while SION-451 anchors dual combinations, with data expected mid-2026.
-
A novel approach targeting the NBD1 domain in CFTR aims to address the unmet need in cystic fibrosis by increasing the proportion of patients achieving normal CFTR function. Two NBD1 stabilizers are completing phase 1, with promising PK and safety data, and combination studies are set to begin, supported by a strong financial position and validated assays.
-
A novel approach targeting the NBD1 domain in CFTR protein aims to address significant unmet needs in cystic fibrosis, with two promising compounds in phase I and a robust pipeline supported by recent IPO funding. The strategy focuses on dual combinations to achieve normal CFTR function, with key proof-of-concept data expected by mid-2026.